Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

$CGON
Get the next $CGON alert in real time by email
SC 13G/A 1 UnitedStates_13G__CGoncology.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) CG oncology Inc (Title of Class of Securities) Common Stock (CUSIP Number) 156944100 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 156944100 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 58,658 (7) Sole dispositive power 4,995,679 (8) Shared dispositive power 85,673 (9) Aggregate amount beneficially owned by each reporting person 5,081,352 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 7.57% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: CG oncology Inc Item 1(b) Address of issuer's principal executive offices: 400 Spectrum Center Drive Suite 2040 Irvine, CA 92618 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 156944100 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 5,081,352 (b) Percent of class: 7.57% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 5,081,352 (b) Percent of class: 7.57% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 58,658 (iii) Sole power to dispose or to direct the disposition of: 4,995,679 (iv) Shared power to dispose or to direct the disposition of: 85,673 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
Get the next $CGON alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CGON

DatePrice TargetRatingAnalyst
1/7/2025Buy
TD Cowen
10/24/2024$60.00Buy
UBS
9/23/2024$66.00Outperform
RBC Capital Mkts
8/28/2024$65.00Buy
ROTH MKM
6/28/2024$65.00Buy
BofA Securities
2/20/2024$75.00Overweight
Cantor Fitzgerald
2/20/2024$42.00Neutral
Goldman
2/20/2024$55.00Overweight
Morgan Stanley
More analyst ratings

$CGON
Press Releases

Fastest customizable press release news feed in the world

See more
  • CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

    - Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology's clinical trial program, including translational data, planned - IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part

  • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

    - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

  • Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

    – Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that 83 out of 110 patients (75.5%) achieved a complete response (CR) at any time in a Phase 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer wit

$CGON
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CGON
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CGON
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CGON
SEC Filings

See more

$CGON
Financials

Live finance-specific insights

See more
  • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

    - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

  • Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

    – 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unr

  • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

    IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenti

$CGON
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more